228. Bronchiolitis obliterans Clinical trials / Disease details
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
Showing 1 to 10 of 97 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05654922 (ClinicalTrials.gov) | February 6, 2023 | 8/12/2022 | Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis ObliteransProgression in Participants W ... | A Phase 3, Open-label, Randomized, Standard of Care-controlled, Parallel Study Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants With a Bilateral Lung Transplant A Phase 3, Open-label, Randomized, Standard of Care-controlled, Parallel Study Arm Study to Demonstr ... | Pre-Bronchiolitis Obliterans Syndrome | Drug: ARINA-1;Other: Standard of care only | Renovion, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 100 | Phase 3 | United States |
| 2 | NCT05413356 (ClinicalTrials.gov) | June 1, 2022 | 7/6/2022 | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Ruxolitinib for Newly Diagnosed Bronchiolitis ObliteransSyndrome After Allogeneic Hematopoietic Stem ... | Bronchiolitis Obliterans Syndrome;Hematologic Malignancy | Drug: Ruxolitinib | First Affiliated Hospital of Zhejiang University | Second Affiliated Hospital, School of Medicine, Zhejiang University;Zhejiang Provincial People's Hospital;The First Affiliated Hospital of Zhejiang Chinese Medical University;Sir Run Run Shaw Hospital;First Affiliated Hospital of Wenzhou Medical University;Ningbo No. 1 Hospital;The Affiliated People's Hospital of Ningbo University;Jinhua Central Hospital;Taizhou Hospital;Union hospital of Fujian Medical University;Xiangya Hospital of Central South University Second Affiliated Hospital, School of Medicine, Zhejiang University;Zhejiang Provincial People's Hos ... | Recruiting | 18 Years | 65 Years | All | 50 | Phase 2 | China |
| 3 | EUCTR2018-003205-25-DK (EUCTR) | 15/02/2022 | 28/09/2021 | Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis obliterans syndrome after double lung transplantation. Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in pa ... | A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation - BOSTON-2 A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effi ... | Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Chronic Lung Allograft Dysfunction / Bronchiolitis ObliteransSyndrome in Patients post Double Lung T ... | Product Name: Liposomal Cyclosporine A Product Code: L-CsA INN or Proposed INN: Ciclosporin (Ciclosporinium) Other descriptive name: CICLOSPORIN A Product Name: Liposomal Cyclosporine A Product Code: L-CsA INN or Proposed INN: Ciclosporin(Ciclospori ... | Zambon SpA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 110 | Phase 3 | France;United States;Spain;Belgium;Austria;Denmark;Israel;Germany;United Kingdom | ||
| 4 | NCT04908735 (ClinicalTrials.gov) | November 12, 2021 | 26/5/2021 | Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant | Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study | Hematopoietic Stem Cell Transplant (HSCT);Bronchiolitis Obliterans (BO) | Drug: Ruxolitinib | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 5 Years | 25 Years | All | 40 | Phase 2 | United States |
| 5 | NCT04655508 (ClinicalTrials.gov) | May 21, 2021 | 10/11/2020 | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 =10% From Pre Transplantation Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placeb ... | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 =10% From Pre Transplantation Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placeb ... | Stem Cell Transplant Complications;Respiratory Disease;Bronchiolitis Obliterans | Drug: Placebo;Drug: Seretide | Assistance Publique - Hôpitaux de Paris | GlaxoSmithKline | Recruiting | 6 Years | 17 Years | All | 243 | Phase 3 | France |
| 6 | NCT04239989 (ClinicalTrials.gov) | April 8, 2021 | 30/12/2019 | Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib for the Treatment of Bronchiolitis ObliteransSyndrome After Donor Hematopoietic Cell Tran ... | A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT) A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchio ... | Bronchiolitis Obliterans | Drug: Itacitinib;Drug: Itacitinib Adipate | M.D. Anderson Cancer Center | NULL | Recruiting | 18 Years | 75 Years | All | 15 | Phase 1 | United States |
| 7 | NCT04640025 (ClinicalTrials.gov) | March 10, 2021 | 18/11/2020 | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of I ... | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110) A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants P ... | Myelofibrosis;Postlung Transplant (Bronchiolitis Obliterans);Chronic Graft Versus Host Disease | Drug: itacitinib | Incyte Corporation | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States;Austria;Belgium;Canada;Germany;Greece;Israel;Italy;Spain |
| 8 | NCT03603899 (ClinicalTrials.gov) | September 9, 2020 | 4/10/2017 | Hp129 Xenon Imaging and BOS in Lung Transplantation | Imaging and Understanding Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation With Hyperpolarized 129Xenon MR Lung Imaging Imaging and Understanding Bronchiolitis ObliteransSyndrome (BOS) in Lung Transplantation With Hyperp ... | Bronchiolitis Obliterans | Drug: Hp 129Xenon | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 6 Years | N/A | All | 45 | Phase 1/Phase 2 | United States |
| 9 | EUCTR2019-002987-29-AT (EUCTR) | 23/04/2020 | 21/01/2020 | Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syndrome after Single or Double Lung Transplantation. Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in pa ... | An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed the participation to BOSTON 1 and BOSTON 2 studies. An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients wit ... | Bronchiolitis Obliterans Syndrome in Patients post Single or post Double Lung Transplantation MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Bronchiolitis ObliteransSyndrome in Patients post Single or post Double Lung Transplantation MedDRA ... | Product Name: Liposomal Cyclosporine A Product Code: L-CsA INN or Proposed INN: Ciclosporin (Ciclosporinium) Other descriptive name: CICLOSPORIN A Product Name: Liposomal Cyclosporine A Product Code: L-CsA INN or Proposed INN: Ciclosporin (Ciclosporinium) Other descriptive name: CICLOSPORIN A Product Name: Liposomal Cyclosporine A Product Code: L-CsA INN or Proposed INN: Ciclosporin(Ciclospori ... | Zambon SpA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 220 | Phase 3 | France;United States;Spain;Belgium;Austria;Israel;Germany;United Kingdom | ||
| 10 | NCT04039347 (ClinicalTrials.gov) | March 3, 2020 | 19/7/2019 | Open-Label, Extension Trial to Demonstrate the Effectiveness and Safety of L-CsA Plus Standard of Care in the Treatment of BOS in Patients Post Single or Double Lung Transplant Open-Label, Extension Trial to Demonstrate the Effectiveness and Safety of L-CsA Plus Standard of Ca ... | A Phase III, Multicenter Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosprine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single or Double Lung Transplantation A Phase III, Multicenter Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and S ... | Bronchiolitis Obliterans;Obliterative Bronchiolitis;Bronchiolitis Obliterans Syndrome | Drug: Liposomal Cyclosporine A 5 mg;Drug: Liposomal Cyclosporine A 10 mg | Zambon SpA | NULL | Enrolling by invitation | 18 Years | N/A | All | 220 | Phase 3 | United States;Austria;Belgium;France;Germany;Israel;Spain;United Kingdom |